This understanding will be utilized to build models that describe the gut microbiome–portal vein–liver axis and to identify biomarkers for predicting, preventing and treating metabolic liver diseases. Based on clinical observational and interventional study, omics-based techniques will provide novel insight into the role of gut microbiota dysbiosis in the pathogenesis of NAFLD, NASH and alcoholic liver disease.
MicrobLiver is a consortium of leading basic scientists and clinical researchers. The principal investigator, Torben Hansen, is professor at Novo Nordisk Foundation Center for Basic Metabolic Research. Other significant partners of the consortium include Matthias Mann, Jelle Matthijnssens, Peer Bork, Aleksander Krag, Flemming Bendtsen, Jonel Trebicka and Allan Vaag.
Six of 12 clinical studies are centered at FLASH and professor Aleksander Krag is responsible for the clinical part of MicrobLiver.
The project was awarded DKK 60 million by Novo Nordic Foundation Challenge Program in 2016 and runs until 2021.
